Skip to main content

DynaCirc CR Side Effects

Generic name: isradipine

Medically reviewed by Drugs.com. Last updated on Mar 9, 2024.

Note: This document contains side effect information about isradipine. Some dosage forms listed on this page may not apply to the brand name DynaCirc CR.

Applies to isradipine: oral capsule.

Serious side effects of DynaCirc CR

Along with its needed effects, isradipine (the active ingredient contained in DynaCirc CR) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking isradipine:

More common

Less common

Get emergency help immediately if any of the following symptoms of overdose occur while taking isradipine:

Symptoms of Overdose

Other side effects of DynaCirc CR

Some side effects of isradipine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to isradipine: oral capsule, oral tablet extended release.

General

Isradipine (the active ingredient contained in DynaCirc CR) is generally well-tolerated. Most side effects occurred as commonly as with placebo in placebo-controlled trials, except for flushing, headache, and palpitations.[Ref]

Cardiovascular

Cardiovascular side effects are among the most common, and are related to the vasodilatory properties of isradipine (the active ingredient contained in DynaCirc CR) Peripheral edema and flushing are reported in 3% to 14% of patients, being more common at higher doses. Dizziness occurs in 3% to 8% of patients.[Ref]

Palpitations or a greater awareness of heart beats is reported in 1% to 5% of patients. Flushing and palpitations are more likely with dosages greater than 5 mg daily; women have reported flushing more than men. Edema was reported in up to 22% of patients in one study (mean dose was 5.9 mg TID). In large studies, the incidence of edema is less than 3%, and appeared to be more likely in patients greater than 60 years of age.

Isradipine does not appear to adversely affect plasma lipids.[Ref]

Nervous system

Nervous system side effects are probably related to the vasodilatory effects of isradipine (the active ingredient contained in DynaCirc CR) Headache is reported in 9% to 30% of patients and fatigue is reported in 7% of patients.[Ref]

Headache was reported in up to 16% of patients in one study, although the mean dose was 5.9 mg three times daily to treat angina pectoris. Headache is more likely with dosages greater than 5 mg daily. Visual disturbances are reported in less than 2% of patients. Sleep disturbances are reported in 0.1% of patients.[Ref]

Gastrointestinal

Gastrointestinal side effects are unusual, and include constipation in less than 2% of patients.[Ref]

Anorexia, nausea, vomiting, and diarrhea are reported in less than 4% of patients.[Ref]

Respiratory

Respiratory system complaints include dyspnea and cough in 2% of patients.[Ref]

Musculoskeletal

Musculoskeletal pain is reported in 1% of patients.[Ref]

Dermatologic

Dermatologic complaints of "disturbed skin sensation" are reported in less than 4% of patients.[Ref]

Hypersensitivity

Hypersensitivity reactions to isradipine (the active ingredient contained in DynaCirc CR) are rare. Pruritus, urticaria, and angioedema have been reported.[Ref]

References

1. Multum Information Services, Inc. Expert Review Panel

2. Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment. J Intern Med. 1994;236:37-42.

3. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine (isradipine-CR). J Clin Pharmacol. 1995;35:239-43.

4. Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF. Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients. J Cardiovasc Pharmacol. 1992;19:s53-7.

5. Walton T, Symes LR. Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. Clin Pharm. 1993;12:261-75.

6. Sundstedt CD, Ruegg PC, Keller A, Waite R. A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension. Am J Med. 1989;86:98-102.

7. Ruegg PC, Nelson DJ. Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris. Am J Med. 1989;86:70-4.

8. De Keyser P, Bouve J, Clement D, Degraef R, Meurant JP, Rorive G, Van Thillo J. Isradipine in essential hypertension: the Belgian General Practitioners' Study. Am J Med. 1989;86:103-9.

9. Yodfat Y, Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH ResearchGroup. Am J Hypertens. 1993;6:s57-61.

10. Samad A, Khan AH, Hashmi MS. Efficacy, safety, and tolerability of isradipine in hypertension as used in general practice in a developing country (Pakistan). Am J Hypertens. 1993;6:s54-6.

11. Luomanmaki K, Inkovaara J, Hartikainen M, Helin M, Viikari J, Kataja M, Ekman K, Harjula K. Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH). J Cardiovasc Pharmacol. 1992;20:296-303.

12. Hermans L, Bogaert M, Degaute JP, Rorive G, Six R, Bara L, Lanssiers P, De Keyser P, Westelinck KJ. Tolerability of isradipine in the treatment of mild-to-moderate hypertension in general practice: a large-scale surveillance study. J Cardiovasc Pharmacol. 1992;19:s38-45.

13. Marcus AO. Antihypertensive therapy with the calcium channel blocker isradipine - an appropriate choice for the diabetic patient with hypertension - a review. Curr Ther Res Clin Exp. 1993;54:763-778.

14. Farsang C, Kapocsi J, Kiss I, Torok E, Kerkovits G, Hollo J, Javor T. Hungarian isradipine study (HIS): long-term (3-year) effects on blood pressure and plasma lipids. Am J Hypertens. 1994;7 Suppl 7:s56-60.

15. Rochagoncalves F, Moura B, Pereiramiguel JM, Correanunes A, Marianopego G. Isradipine in the treatment of mild-to-moderate hypertension in geriatric patients. Am J Hypertens. 1994;7 Suppl 7:s64-6.

16. Weiss RJ. A large, prospective, open-label study of isradipine in patients with essential hypertension. Clin Ther. 1994;16:647-52.

17. Hermans L, Deblander A, Dekeyser P, Scheys I, Lesaffre E, Westelinck KJ. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. Br J Clin Pharmacol. 1994;38:335-40.

18. Blecker D. Antihypertensive therapy with isradipine in patients with special safety concerns. Angiology. 1994;45:997-1008.

19. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. Am J Hypertens. 1995;8:87-9.

20. Brogden RN, Sorkin EM. Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs. 1995;49:618-49.

21. Kubota K, Pearce GL, Inman WHW. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol. 1995;48:1-7.

22. Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR. A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension. J Clin Pharmacol. 1995;35:484-92.

23. Tomlinson B, Woo J, Critchley JAJH, Or KKH, Chan TYK, Sanderson JE. Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension. Am J Hypertens. 1994;7 Suppl 7:s35-9.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer